A Efficacy and Tolerability Study of TEGAFOX Sequential S-1 in the Treatment of Adjuvant Chemotherapy for Gastric Cancer

Inclusion Criteria: * 75≧Age≧18 * Histologically or cytologically confirmed gastrointestinal cancer * Stage Ⅱ or Ⅲ or Ⅳ * ECOG ≦2 * Accept the gastric cancer radical resection * Life expectancy of at least three months * Written informed consent to participate in the trial Exclusion Criteria: * History of severe hypersensitivity reactions to the ingredients of S-1\\TF\\5-FU/calcium folinate or oxaliplatin * Inadequate hematopoietic function which is defined as below: * white blood cell (WBC) less than 5x10\^9/L * absolute neutrophil count (ANC) less than 2x10\^9/L * platelets less than 100\*10\^9/L * Inadequate hepatic or renal function which is defined as below: * serum bilirubin greater than 2 times the upper limit of normal range * alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.5 times the ULN if no demonstrable liver metastases or greater than 5 times the ULN in the presence of liver metastases * blood creatinine level greater than 2 times ULN * Presence of peripheral neuropathy * Receiving a concomitant treatment with other fluoropyrimidine drug or flucytosine drug * Women who is pregnant or lactating or fertile women of child-bearing potential unless using a reliable and appropriate contraceptive method throughout the treatment period (Including male) * Psychiatric disorder or symptom that makes participation of the patient difficult; * Concomitant illness that might be aggregated by active, non-controlled disease such as congestive heart failure, ischemic heart disease, uncontrolled hypertension or arrhythmia with in six months * Severe complication(s), e.g., paresis of intestines, ileus, radiographically confirmed interstitial pneumonitis or pulmonary fibrosis, glomerulonephritis ,renal failure, poorly-controlled diabetes